WHO Seeks Senior Regulatory Reviewer to Strengthen Africa’s Clinical Trial Oversight
WHO is recruiting a Senior Regulatory Reviewer for its AVAREF clinical trial pilot, a two-month consultancy designed to help strengthen the continent’s clinical development oversight systems. The position sits inside WHO’s Africa program and centers on one of the most persistent barriers to clinical research in the region: slow, uneven, and fragmented review of clinical trial applications across national ethics and regulatory bodies.
The assignment is not administrative. It is built around technical review, mentorship, and systems harmonization for the clinical component of trial dossiers. The consultant will work with AVAREF’s Secretariat and a newly assembled network of reviewers drawn from 16 member countries, where 48 experts have been nominated across clinical, non-clinical, and quality domains. The immediate target is a functioning reliance network that can support more coordinated, higher-quality decisions across borders.
A Pilot Built to Reduce Fragmented Review Pathways
AVAREF, short for AdVancing ClinicAl TRials Excellence in AFrica, has spent 19 years building capacity among national regulatory authorities and national ethics committees. The new pilot reflects a more ambitious phase in that effort. Rather than relying on isolated national processes, the program is pushing toward multi-country joint reviews, harmonized procedures, and shared tools that can shorten timelines without lowering scientific standards.
The logic is straightforward. When review systems differ widely from country to country, sponsors face duplicated work, inconsistent expectations, and long delays before a clinical trial can start. For regions already underrepresented in global research, those delays can be enough to discourage trials from being launched at all. A more coherent review architecture can change that equation by improving predictability for developers and raising confidence in the quality of oversight.
The pilot follows an Advisory Committee meeting in Dakar in September 2024 and was shaped by country selection criteria that included trial volume, regional representation, regulatory maturity, and readiness to participate in a reliance-based model. WHO’s framing places clinical trial oversight inside a broader disease-control strategy, linking regulatory capacity to access to innovative medicines, vaccines, and health technologies of assured quality.
A stronger regulatory system is a clinical tool, not just an institutional one.
Coaching Reviewers While Building a Harmonized System
The consultant’s central responsibility is to act as coach, mentor, and second reviewer to the 48 nominated experts over the two-year pilot period. The role is designed to improve how reviewers assess the clinical component of trial dossiers and to help them produce consistent, high-quality assessment reports. In practical terms, that means guiding reviewers through scientific evaluation, dossier interpretation, and decision-making standards that can be applied across countries.
WHO also expects the consultant to contribute to updated guidelines, standard operating procedures, and review checklists. Those documents matter because harmonization is not achieved through policy language alone; it depends on having the same review questions, the same evidence thresholds, and the same working definitions used across institutions. The pilot is also expected to support digital submission systems, coordinated review protocols, and a more formal reviewer pool that can be mobilized for future clinical trial applications.
The consultancy extends beyond trial applications alone. AVAREF also supports scientific advice and facilitated registrations for emergency use authorizations of medicines for public health. That places the reviewer in a broader ecosystem where regulatory review, public health urgency, and clinical development intersect. In outbreak settings, the speed of review can affect whether a product reaches patients in time to matter, but any acceleration still has to preserve the scrutiny needed to protect participants and future users.
What WHO Wants in a Reviewer
The qualifications are unusually demanding because the work combines technical depth, regulatory judgment, and cross-border collaboration. WHO is asking for a doctorate in medicine, biomedical sciences, health sciences, or an advanced university degree in a health-related field. Desirable backgrounds include public health, communicable or non-communicable diseases, toxicology, pharmacology, microbiology, biostatistics, pharmacovigilance, and pharmacoepidemiology.
The experience profile is even more specific. Candidates should have at least 10 years in an internationally recognized national regulatory agency rated at ML-4, along with at least 10 years of experience in medicines regulation, trial dossier review, and the registration of new or existing medicines. Experience with biotherapeutics, biosimilars, and other biologics is also expected. WHO lists expertise in GCP inspection, GCLP, GMP, post-marketing surveillance, and clinical data review for vaccines and drug registration dossiers.
There is also a strong preference for reviewers with clinical specialty expertise in fields such as cardiology, internal medicine, pediatrics, oncology, neurology, obstetrics and gynecology, surgery, or related disciplines. That requirement reflects the realities of dossier assessment: scientific review depends not only on regulatory experience, but also on the ability to judge whether a protocol, safety package, or endpoint strategy makes sense for a specific disease area.
Why the Regulatory Bottleneck Matters for Research in Africa
WHO’s rationale for the post is rooted in a wider structural problem. Africa’s R&D and manufacturing capacity for medicines and vaccines remains low, despite a heavy communicable and non-communicable disease burden. Weak oversight systems, limited staffing, poor transparency, and the scarcity of experts have all contributed to slow trial approval timelines. Developers may be reluctant to bring studies to the continent when the review path is uncertain or prolonged.
The pilot tries to change that by building a dependable pool of reviewers and aligning processes across countries. If successful, it could make Africa a more attractive destination for trials while also strengthening local control over the science taking place within national borders. The stakes are high because clinical trial oversight is the point at which participant protection, scientific validity, and public trust converge.
The consultant will report to the Technical Officer and Implementation Research Portfolio Coordinator within the AVAREF Secretariat at WHO-AFRO. The assignment is home-based, with a monthly band of USD 7,000 to 9,980 excluding travel costs. WHO says the vacancy may also be used to identify candidates for similar consultancies at the same level.
One line in the posting captures the broader ambition: the reviewer pool is meant to become a resource for clinical trial applications, not just a temporary project team. If that network holds, the pilot could leave behind more than training workshops and draft procedures. It could leave a working model for how regional reliance, standardized review, and mentorship can compress timelines without compromising scientific rigor.